Foxc2 over-expression in bone marrow mesenchymal stem cells stimulates osteogenic differentiation and inhibits adipogenic differentiation.
You W., Fan L., Duan D., Tian L., Dang X., Wang C.
Animal Study, published in Mol Cell Biochem (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Mol Cell Biochem (2014)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 24122419
- DOI
- 10.1007/s11010-013-1851-z
Abstract (original English)
The forkhead box C2 (Foxc2) protein, a member of the forkhead/winged helix transcription factor family, is strongly expressed in developing embryo and is required in various developmental processes. However, the precise function of Foxc2 in osteoblast differentiation remains largely unknown. The present study investigated the role of Foxc2 overexpression on osteogenic and adipogenic differentiations. In our experiment, rabbit bone marrow mesenchymal stem cells (BMSCs) were transduced with lentiviral vectors containing Foxc2 or green fluorescent protein (GFP), and the gene expression and biological activity of Foxc2 were examined in vitro. The results showed that the mRNA and protein expressions of Foxc2 were stable and high in cells transduced with Foxc2 compared with those transduced with GFP. The overexpression of Foxc2 increased the mRNA and protein levels of COLI, OCN, and OPN; enhanced the activity of ALP after osteogenic induction; and decreased the expression of PPARγ-2 and the total droplet number after adipogenic induction. In addition, Foxc2 enhanced the expression of β-catenin, an important modulator of osteoblastogenesis. XAV939, a small molecule inhibitor of the Wnt-β-catenin pathway, suppressed Foxc2-mediated regulation of BMSC differentiation. These findings demonstrate that the overexpression of Foxc2 gene in BMSCs may promote osteogenic differentiation and inhi
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.